Sanford Burnham
  • Sanford Burnham
  • Twitter
  • Facebook
  • Youtube
  • Navigate Sanford-Burnham
    • Main Site
    • Our Mission
    • Research
    • Talent
    • Technology
    • Training & Education
    • Our Supporters
    • News

Beaker

Sanford-Burnham Science Blog

Subscribe

Searching for causes of neuron death in Alzheimer’s and TBI

by Heather Buschman, Ph.D. on November 8, 2012 at 5:26 am | 6 Comments
Full Article
In Alzheimer's and traumatic brain injury, neurons (red) are killed off by the protein appoptosin

In Alzheimer's and traumatic brain injury, neurons (red) are killed off by the protein appoptosin

Sanford-Burnham researchers discovered that the protein appoptosin prompts neurons to commit suicide in several neurological conditions—giving them a new therapeutic target for Alzheimer’s disease and traumatic brain injury.

Dying neurons lead to cognitive impairment and memory loss in patients with neurodegenerative disorders–conditions like Alzheimer’s disease and traumatic brain injury. To better diagnose and treat these neurological conditions, scientists first need to better understand the underlying causes of neuronal death.

Enter Huaxi Xu, Ph.D., professor in Sanford-Burnham’s Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research. He and his team have been studying the protein appoptosin and its role in neurodegenerative disorders for the past several years. Appoptosin levels in the brain skyrocket in conditions like Alzheimer’s and stroke, and especially following traumatic brain injury.

Appoptosin is known for its role in helping the body make heme, the molecule that carries iron in our blood (think “hemoglobin,” which makes blood red). But what does heme have to do with dying brain cells? As Xu and his group explain in a paper they published recently in the Journal of Neuroscience, excess heme leads to the overproduction of reactive oxygen species, which include cell-damaging free radicals and peroxides, and triggers apoptosis, the carefully regulated process of cellular suicide. This means that more appoptosin and more heme cause neurons to die.

Read More

Where are they now? Meet three entrepreneurial alumni

by Heather Buschman, Ph.D. on July 19, 2012 at 5:38 am | 0 Comments
Full Article
Left to right: Quinn Deveraux, John Timmer, and Brendan Eckelman

Left to right: Quinn Deveraux, John Timmer, and Brendan Eckelman

Brendan Eckelman, Quinn Deveraux, and John Timmer are three Sanford-Burnham alumni who turned to the entrepreneurial side of science, with a goal to translate research findings into new therapies. Eckelman (2003-2007) and Timmer (2004-2009) both conducted their graduate research in Guy Salvesen’s laboratory, while Quinn Deveraux was a postdoctoral fellow (1996-2000) in the laboratory of Sanford-Burnham’s CEO, John C. Reed. During their time at Sanford-Burnham, all three made contributions to the apoptosis field—the study of programmed cell death, a process that can malfunction in cancer and other diseases.

After earning his Ph.D., Eckelman joined Deveraux’s group at the Genomics Institute of the Novartis Research Foundation (GNF). At GNF they were tasked with generating therapeutic antibodies for the Novartis pipeline. Ready to leave the pharma environment in late 2009, the two were introduced to Mark Lappe by Reed. Shortly thereafter, Eckelman, Deveraux, and Lappe founded Inhibrx, a biotechnology company dedicated to discovering new therapeutic antibodies for cancer, inflammatory diseases, and metabolic disorders.

Inhibrx focuses on one of the biopharma industry’s greatest needs—translation of validated and novel drug targets into clinical candidates.

Read More

Cells in the balance

by Josh Baxt on May 31, 2011 at 4:10 pm | 0 Comments
Full Article
Dr. Kristiina Vuori and Dr. John Reed are working to find new ways to help cancer cells die.

Dr. Kristiina Vuori and Dr. John Reed are working to find new ways to help cancer cells die.

May is National Cancer Research Month, created by Congress in 2007 to recognize the American Association of Cancer Research (AACR) for its contributions to the field. To honor AACR and highlight some of the important cancer research being done at Sanford-Burnham, throughout May we posted a series of articles on the ongoing work in our National Cancer Institute-designated Cancer Center. The vast majority of this research is made possible by funding from the National Institutes of Health (NIH), which includes the National Cancer Institute (NCI).

Cells contain a complex mixture of opposing forces striving for balance. When these mechanisms work properly, cells are healthy. However, if one side gains the upper hand, balance is lost and disease can result.

Programmed cell death, or apoptosis, is a critical cellular quality control mechanism regulated by small squads of pro- and anti-apoptotic proteins. In healthy cells, these opposing mechanisms maintain the life/death balance. However, they can also go awry in a number of diseases. In particular, cancers often over-express anti-apoptotic proteins, giving them a measure of immortality.

Sanford-Burnham’s NCI-designated Cancer Center has led the way on cell death research. In a recent paper, Dr. Guy Salvesen, who directs the Apoptosis and Cell Death Program, and colleagues showed how an enzyme, caspase-8, can teeter between advancing or defeating apoptosis, depending on factors in the cell. Caspases are critical regulators of apoptosis, and understanding their function could lead to new treatments.

Read More

Mitochondria 101

by Heather Buschman, Ph.D. on December 3, 2010 at 7:24 am | 5 Comments
Full Article
Cartoon diagram of a mitochondrion, peeled back to reveal the inner membrane and inner workings of the cell's "powerhouse". (Image courtesy of Wikimedia Commons)

Cartoon diagram of a mitochondrion, the "powerhouse" of the cell. (Image courtesy of Wikimedia Commons)

“In the depths of history, a free-living bacterium was engulfed by a larger cell and was neither digested nor destroyed. Instead, it was domesticated. It forged a unique and fateful partnership with its host, eventually becoming the mitochondria of today.” – Ed Yong, Not Exactly Rocket Science, Discover Magazine

Mitochondria are the parts of our cells that we often call the “powerhouse.” Without them, animal cells wouldn’t have the energy they need to sustain life. A mitochondrion is surrounded by two membrane layers, kind of like a little pillow encased in two pillowcases. The inner pillowcase is where most of the action takes place. It’s ruffled, which provides more surface area for the series of chemical reactions that generate ATP, the cell’s currency. Like money, you have to have ATP in order to do things. Cells can cash in ATP to divide, make new proteins, process cellular waste, store fat or do anything else they need to survive (see DNA 101 and Proteins 101).

Because of their role in maintaining a cell’s fuel and energy balance, mitochondria are the subject of intense scrutiny by scientists interested in the molecular underpinnings of metabolism, obesity, diabetes and cancer. But mitochondria also play a role in cell death. Some cells are long-lived (like neurons in the brain), while others turn over quickly (think skin cells). Either way, the process of cellular suicide – called apoptosis – has to be carefully managed in order to both avoid untimely demise and prevent cells from living too long. When called upon, mitochondrial proteins leak out through the outer membrane and into the cell’s cytosol, where they remove the molecular brakes that normally promote survival and activate caspases, enzymes that execute apoptosis. When mitochondrial function or apoptosis go awry, disease can develop – too much cell death causes neurodegenerative diseases like Alzheimer’s, while too little allows cancer cells to avoid destruction.

Tumors Beware, Part 2

by Heather Buschman, Ph.D. on August 23, 2010 at 1:28 pm | 0 Comments
Full Article

Last week we mentioned a lecture Dr. Kristiina Vuori, Sanford-Burnham’s president and director of our NCI-Designated Cancer Center, gave to San Diego’s CONNECTcommunity about the Institute’s many exciting advances in cancer research.So how exactly do Sanford-Burnham researchers put cancer cells in their place?

As Dr. Vuori highlighted in her lecture, scientists in each of Sanford-Burnham Cancer Center’s four programs – Tumor Development, Signal Transduction, Tumor Microenvironment and Apoptosis and Cell Death Research –  are designing new therapies that tackle cancer during every step of the disease’s progression. Here are just a few examples of Sanford-Burnham’s multi-pronged approach, as described by Dr. Vuori…

Read More

San Diego’s Local News Highlights Cancer Finding

by Heather Buschman, Ph.D. on August 2, 2010 at 3:12 pm | 0 Comments
Full Article

San Diego’s Channel 10 News, an ABC affiliate, featured Sanford-Burnham’s Dr. Xiao-kun Zhang and his recent studythat showed how a painkiller related to aspirin can inhibit tumor growth in mice. In the video, Dr. Zhang said:

“[It stops] colon cancers, breast cancers, liver cancers and even prostate cancer and it seems pretty powerful.”

Dr. Zhang and his colleagues took their findings one step further by tweaking the painkiller, called Sulindac, to enhance its anti-cancer effects and reduce the side-effects.

“If we can reduce the side effects, this is a big, big deal,” said Zhang.

Sulindac is currently prescribed to treat pain, fever and arthritis. The study was published in the June 15 issue of the journal Cancer Cell.

Learning How Cancer Works

by Josh Baxt on July 26, 2010 at 2:37 pm | 1 comment
Full Article

The more strategies we adopt in the war on cancer, the more opportunities we will have to develop new medicines. Here’s how Sanford-Burnham scientists approach the fight…

Read More

Cancer Paper Receives National Coverage

by Josh Baxt on June 21, 2010 at 3:29 pm | 0 Comments
Full Article

Sanford-Burnham researcher Dr. Xiao-kun Zhang recently published a paper in the journal Cancer Cell describing how the painkiller Sulindac, a COX-2 inhibitor, encourages cancer cells to commit suicide. The paper went on to detail how the Zhang lab had created a version of Sulindac that kept the cancer killing properties but dispensed with the side effects associated with COX-2 inhibitors.  Today, that paper was highlighted in an article on CBS News Online.

“Sulindac has a very strong impact on cancer activity,” said Xiao-kun Zhang, Ph.D., a professor at Sanford-Burnham and senior author of the study. He said NSAIDs have shown to inhibit the growth of many kinds of cancer, including colon, breast, prostate, and lung. “Our study might help drug makers develop new drugs with anticancer activity.”

To support this groundbreaking research at the Sanford-Burnham Medical Research Institute, please click here.

A pain reliever that does it all

by Heather Buschman, Ph.D. on June 14, 2010 at 9:31 am | 2 Comments
Full Article

Many studies have shown that a daily dose of aspirin can help prevent cancer. Now Sanford-Burnham scientists Dr. Xiao-kun Zhang, Dr. Hu Zhou and others have found a way to block tumor growth by using a related pain reliever called Sulindac. The study, published in the June 15, 2010 issue of the journal Cancer Cell, pieced together the molecular mechanism Sulindac uses to destroy cancer cells, and created a new-and-improved version of Sulindac that does an even better job of it.

Read More

No Exit: Helping Cancer Cells Die

by Josh Baxt on May 11, 2010 at 3:50 pm | 2 Comments
Full Article

Cancer cells use anti-apoptotic (anti-cell death) proteins in the Bcl-2 family to evade treatment. Even when slammed with harsh doses of radiation or chemotherapy, cancer cells can harness these proteins to evade death. However, that escape route may be closing. In the past few days, Dr. Maurizio Pellecchia has published two papers that shed new light on how Bcl-2 proteins work and how we can defeat them.

Read More

Search

Find more information

  • About Beaker
  • Contact us
  • Donate

Please take a quick survey

Which of these items describes you?

Select all that apply. (Question 1 of 5)

Categories

  • Basic Research
  • Cancer
    • Apoptosis & Cell Death Research
    • Signal Transduction
    • Tumor Development
    • Tumor Microenvironment
  • Children's Health
    • Genetic Diseases
    • Muscle Development & Regeneration
    • RNA Biology
  • Diabetes & Obesity
    • Cardiovascular Pathobiology
    • Metabolic Signaling & Disease
  • Drug Discovery
  • Events
  • Graduate School of Biomedical Sciences
  • Grants
  • Infectious & Inflammatory Diseases
    • Bioinformatics & Systems Biology
    • Infectious Diseases
    • Inflammatory Diseases
  • Nanomedicine
  • Neuroscience, Aging, & Stem Cells
    • Degenerative Diseases
    • Development & Aging
    • Stem Cells
  • Other
  • People
  • Sanford-Burnham Supporters
  • Translational Medicine

Search by Keyword

Alzheimer's disease CCRA CIRM collaboration commitment communication community Conrad Prebys Center for Chemical Genomics Daniel Kelly Erkki Ruoslahti Evan Snyder Florida Hospital Fred Levine Genetic Disease Program Guy Salvesen Hudson Freeze John Reed Kristiina Vuori La Jolla Lake Nona Metabolic Signaling metabolism NIH Orlando personalized medicine Prebys Center press proteins Rare Diseases Rare disease symposium research publications Robert Wechsler-Reya Santa Barbara Sara Courtneidge Stem Cells Steven Smith Stuart Lipton T. Denny Sanford technology Translational Research Institute tumor microenvironment Tumor Microenvironment Program Video Yu Yamaguchi Ze'ev Ronai

© Sanford-Burnham Medical Research Institute. All rights reserved.

Get Cloud PHP Hosting on CatN